Cover Image
市場調查報告書

Bosatria(Mepolizumab)(氣喘治療藥):市場預測與分析

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 316084
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
Bosatria(Mepolizumab)(氣喘治療藥):市場預測與分析 Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 66 Pages
簡介

Bosatria是GSK所開發以IL-5(控制嗜酸性粒細胞活性化的細胞激素的一種)為目標的人體化單株抗體。當初是開發作好酸性症候群的治療藥,但受到CHMP(歐洲醫藥品委員會)裁定「Bosatria在氣喘方面風險平衡上有正面效益的數據不足」這個評估的影響,GSK收回認証程序。雖然GSK宣稱自家公司的重量級產品Advair/Seretide在全世界有數十美金的銷售額,但Bosatria由於只限定用於部分難治性患者身上,難以期待可達到那個地位。

本報告提供氣喘的治療藥之一,Bosatria(Mepolizumab)的全球市場相關分析,提供氣喘概要和治療方法,競爭的企業、藥品概要,市場競爭概況,彙整Bosatria的商品資訊(特色·功效·安全性等),全球主要國家的市場銷售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病管理

  • 診斷·治療概要
    • 診斷
    • 治療的指南,臨床診療,有代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要
  • 競爭企業的策略性評估

第6章 未滿足需求與市場機會

  • 概要
  • 為了管理嚴重氣喘的個體化治療
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 改善病人依從性
  • 降低氣喘藥物的治療費用
  • 恰當的診斷兒童氣喘

第7章 開發平台評估

  • 概要
  • 臨床實驗中有前途的醫藥品

第8章 Bosatria(Mepolizumab)

  • 概要
  • 功效
  • 安全性
  • 給藥·劑型
  • 在臨床方面的潛在性地位
  • 在商業方面的潛在性地位
  • 價格設定和醫療費給付
  • SWOT分析
  • 預測

第9章 附錄

圖表一覽

目錄

GlobalData has released its new PharmaPoint Drug Evaluation report, "Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

GSK's Bosatria (mepolizumab) is a humanized mAb targeting IL-5, a cytokine that regulates the activation of eosinophils. It was originally developed for the treatment of hypereosinophilic syndrome, but GSK withdrew its authorization application after the CHMP determined that the data were insufficient to conclude whether there is a positive benefit-risk balance for Bosatria in asthma (GSK, press release, July 29, 2009). GSK boasts multibillion dollar sales for its blockbuster, Advair/Seretide, but Bosatria is not expected to reach this status, since it will only be used in a limited number of refractory patients.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Bosatria including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Bosatria for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Bosatria performance
  • Obtain sales forecast for Bosatria from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Personalized Therapies to Control Severe Asthma
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Better Patient Compliance
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Lower Cost of Asthma Medications
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Proper Diagnosis of Asthma in Children
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Bosatria (Mepolizumab)

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Asthma Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Author/Reviewer
    • 9.6.3. Reviewer
    • 9.6.4. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Unmet Need and Opportunity in Asthma
  • Table 8: Asthma - Late Stage Pipeline, 2014
  • Table 9: Product Profile - Bosatria
  • Table 10: Efficacy of Bosatria Versus Placebo
  • Table 11: Bosatria's Safety Profile
  • Table 12: Bosatria SWOT Analysis, 2012
  • Table 13: Global Sales Forecast ($) for Bosatria, 2013-2023
  • Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023
Back to Top